CDK4 and breast cancer: Multiple studies have clarified that PI3K inhibitors are beneficial in enhancing the sensitivity of PIK3CA mutant TNBC to CDK4/6 inhibitors (Asghar et al., 2017), and have a good effect on HR+ breast cancer carrying PIK3CA mutations (Di Leo et al., 2018), which indicates the potential of combined targeted therapy.